Follicular lymphoma

This early-stage trial is testing whether a second infusion of a patient's own genetically modified immune cells (CAR T-cells) can safely treat B-cell lymphoma that has returned after an initial successful response. The study enrolls people with diffuse large B-cell or follicular…

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This study tests whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their ca…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…

This study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …

This study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…

Researchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…

This study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …

This phase 2 trial is testing whether combining two drugs, mosunetuzumab and zanubrutinib, can help people with follicular lymphoma whose cancer has returned or stopped responding to previous treatment. The study will enroll 56 participants and measure how many achieve a complete…

This study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…

This phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…

Researchers are testing an experimental drug called epcoritamab in Chinese adults with B-cell non-Hodgkin lymphoma. The trial gives epcoritamab alone or combines it with standard chemotherapy drugs (R-CHOP or R2). The main goals are to check safety and see how well the cancer res…

This study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (R-CHOP) helps people with a hard-to-treat type of lymphoma called ABC-DLBCL. About 75 adults aged 18-65 with a poor prognosis will receive the combo for 6 cycles, then take ibrutinib alone for 1…

This Phase 3 trial tests whether adding tafasitamab to lenalidomide and rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer worsening. About 654 participants receive either the three-drug combo or lenalidomide plus rituximab …

This phase 2 trial tests whether psilocybin, the active compound in magic mushrooms, combined with psychotherapy can help adults with moderate to severe cannabis use disorder reduce or stop their cannabis use. Participants receive two doses of psilocybin alongside motivational en…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…

This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two…

This study tests whether combining two drugs, epcoritamab and lenalidomide, can shrink or eliminate tumors in people with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. About 29 adults with stage 1-3a disease who need treatment will rece…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mo…

This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…

This phase 3 trial tests whether adding lenalidomide to rituximab maintenance therapy works better than rituximab alone for people with relapsed follicular lymphoma who cannot have a stem cell transplant. About 128 participants will receive either the combination or rituximab alo…

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This study looks at whether adding the drug rituximab to standard radiation therapy helps people with early-stage follicular lymphoma stay cancer-free longer. About 81 patients with stage I or II low-grade lymphoma are being randomly assigned to get radiation alone or radiation p…

This trial is testing whether adding the experimental drug tazemetostat to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or high-risk follicular lymphoma. The study has two parts: first, to find…

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…

This phase 2 trial is testing a new combination of drugs, golcadomide and rituximab, in 90 people with newly diagnosed advanced follicular lymphoma. The goal is to see if this combination can improve complete remission rates compared to standard treatments. The study is active bu…

This phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can…

This Phase 2 trial tests an investigational drug called odronextamab in 515 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The main goal is to see if it shrinks tumors a…

This study tests a gene therapy (AAV2-hAQP1) injected into the saliva glands to see if it can safely increase saliva production in people with long-term dry mouth after radiation for head and neck cancer. About 276 adults who completed radiation at least 3 years ago will receive …

This early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…

This study tests whether a daily 10 mg pill called Xanamem can safely slow memory and function loss in people with mild or moderate Alzheimer's dementia. About 247 participants will receive either Xanamem or a placebo for 36 weeks, with an option to continue the drug for up to 10…

This study tests whether a very low dose of radiation (4 Gy) can control slow-growing B-cell lymphoma in the eye socket. About 50 adults with stage I-IV indolent lymphoma or mantle cell lymphoma will receive this targeted treatment. The goal is to shrink or stop the cancer while …

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…

This Phase 3 study tests whether a new combination of drugs (mosunetuzumab plus lenalidomide) works better than the current standard (rituximab plus lenalidomide) for people with follicular lymphoma that has returned after at least one prior treatment. About 478 participants will…

This phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This study is testing a drug called acalabrutinib, alone or together with other drugs (rituximab and lenalidomide), in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see how safe these combinations are and whether they can…

This study tests an experimental drug called epcoritamab given together with other anti-cancer medicines in adults with Non-Hodgkin lymphoma (NHL), a type of blood cancer. About 496 participants will receive different combinations depending on their lymphoma subtype and treatment…

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…

This phase 3 trial compares a shorter chemotherapy regimen (4 cycles) against the standard 6 cycles, both combined with immunotherapy, for people with newly diagnosed, high-tumor-burden follicular lymphoma. The goal is to see if the shorter treatment is just as effective at keepi…

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …

This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the mix. The study includes 33 participants with stage II to …

This early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults an…

This study tests a new procedure called BEAM (Bariatric Endoscopic Antral Myotomy) to help people with obesity lose weight. The procedure uses a tube down the throat to make small cuts in the stomach muscle, aiming to change how the stomach empties. Twenty adults with a BMI betwe…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults will receive the antibody combination before and during chemo. The g…

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and…

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seve…

This early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…

This phase 3 trial compares a new immunotherapy called epcoritamab (given as a shot under the skin) to standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 483 participants will be randomly assigned to re…

This study tests whether a less invasive heart valve replacement (TAVR) is safe and effective for people with moderate aortic stenosis, a condition where the heart's aortic valve is partially blocked. About 650 participants will receive the TAVR device and be monitored for compli…

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants ha…

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to get eithe…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This study tests whether a once-weekly medication (efanesoctocog alfa) can improve or prevent joint damage in 37 people with moderate or severe hemophilia A. Participants receive the drug for 12 months, and doctors use ultrasound and MRI to check joint health. The goal is to see …

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This study looks at how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in normal medical pr…

This study tests whether the drug AG-120 can safely slow or stop the growth of a rare bone cancer called chondrosarcoma that has a specific IDH1 gene mutation. Six adults with advanced or recurrent grade 2 or 3 chondrosarcoma will receive the drug. The main goal is to see how lon…

This study looks at two different approaches to help community hospitals start treating opioid use disorder in patients. One approach is basic training and education, while the other adds extra support like practice facilitation. The goal is to see which method works better at ge…

This phase 3 trial tests whether a personalized cell therapy called tisagenlecleucel (CAR-T) works better than standard treatments for adults with follicular lymphoma that has come back or stopped responding. About 109 participants will receive either the CAR-T infusion or standa…

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This study tests a new device called the Edwards EVOQUE eos mitral valve replacement system. It is for people with a leaky mitral valve who are too high-risk for open-heart surgery. The study will check if the device is safe and works well by looking at complications, heart funct…

This study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the tri…

This study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) can shrink tumors in people with untreated follicular lymphoma. The trial includes 40 adults with stage II to IV disease. The goal is to see if the combination works better than any si…

This study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…

This phase II trial is testing a combination of two drugs—tazemetostat pills and mosunetuzumab injections—in 23 people with follicular lymphoma who have not yet received treatment. The goal is to see if the combination is safe and leads to a complete response (disappearance of ca…

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…

This early-phase study tests a personalized cancer vaccine designed to target each patient's unique tumor mutations. It is given along with pembrolizumab after standard rituximab treatment for follicular lymphoma. The goal is to see if this approach is feasible and can boost the …

This early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…

This study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but i…

This phase 2 trial is testing a combination of two immunotherapy drugs, glofitamab and obinutuzumab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The study includes 47 participants who have not had prior therapy for their lymphoma. The goa…

This phase II trial is testing whether combining rituximab and pembrolizumab, with or without lenalidomide, can help patients with follicular lymphoma or diffuse large B-cell lymphoma that has returned after previous treatment. The study enrolls 53 participants and measures how m…

This phase 2 trial tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over several cycles. The main goal is to see how many achieve a complete re…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests a new drug combination for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment adds tazemetostat (a targeted pill) to a standard chemo-immunotherapy regimen, but uses a shorter course of chemother…

This study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing …

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This study tests a new drug, odronextamab, combined with chemotherapy for people with untreated follicular lymphoma, a type of blood cancer. It compares this new combo to the standard treatment (rituximab plus chemo) to see which works better. About 733 adults will take part, and…

This study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 50 adults will take part to find the best dose and see if the combination is safe and works better than standard …

This was a phase 2 study testing the oral drug tazemetostat in adults with relapsed or refractory follicular lymphoma whose tumors lack an EZH2 gain-of-function mutation. The drug is already approved for this cancer, but researchers wanted to see how well it works in this specifi…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy helps lymphoma patients build stronger immunity. About 26 adults with certain types of B-cell lymphoma will receive the vaccine around their CAR T treatment. The goal is to see if t…

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This phase 2 trial tests the safety and effectiveness of combining two drugs, epcoritamab and tazemetostat, for patients with follicular lymphoma that has relapsed or is refractory. The study plans to enroll 33 adults. Epcoritamab helps the immune system attack cancer cells, whil…

This study tests whether adding an experimental drug called E7777 before standard CAR-T therapy can help people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 30 participants will receive E7777 followed by chemotherapy and a CAR-T produc…

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …

This early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…

This early-phase trial is testing whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy can safely treat aggressive B-cell lymphoma that has come back or not responded to treatment. About 24 adults will receive either DHAX or ICE chemotherapy plus mosunetuz…

This study was designed to test the safety of a device called Valvosoft, which uses ultrasound waves from outside the body to treat moderate aortic valve stenosis. The goal was to see if it could improve valve movement without major complications. However, the trial was withdrawn…

This study monitors the safety of the drug tazemetostat in 145 people with a type of lymphoma (follicular lymphoma) that has come back or not responded to treatment and has a specific gene change (EZH2 mutation). Researchers are tracking side effects and serious reactions during …

This study aimed to compare two ways of managing pain after surgery in people taking buprenorphine for opioid use disorder. One group would continue their usual dose, while the other would receive a lower dose around the time of surgery. The goal was to see which approach better …

This study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma. The drugs work together to help the immune system find and kill cancer cells. The goal is to see how many patients achieve a complete response, meanin…

This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …

This phase 2 trial is testing an experimental cell therapy called JCAR017 for adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, specifically follicular or marginal zone lymphoma. Participants receive chemotherapy followed by a single infusion of their own g…

This study follows adults who previously received a gene therapy (AAV2-hAQP1) for dry mouth caused by radiation treatment for head and neck cancers. Researchers will check for side effects and how well the therapy works over time. About 276 people who already got the therapy in a…

This study tests whether a personalized cell therapy (axicabtagene ciloleucel) works better than standard treatments for people with follicular lymphoma that has come back or stopped responding. About 231 adults with this slow-growing blood cancer will receive either the cell the…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This early-stage trial tests a new cellular immunotherapy for adults with certain B-cell cancers (like lymphomas and leukemias) that have come back. Researchers take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and infuse …

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…

This early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…

This early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …

This study tests a new, less invasive procedure that uses stitches to reduce stomach size in people with mild obesity. The goal is to help with short-term weight loss by making the stomach feel full sooner. Fifteen participants will be followed to see how much weight they lose an…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…

This early-phase trial is testing the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in patients with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The study enrolled only 4 participants to …

This early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the c…

This trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this …

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This study tests a new app called RACS that helps primary care doctors screen older adults for early cognitive decline. The app includes risk questions, a symbol matching task, and voice tasks. Researchers will enroll 500 adults aged 60 and older to see if the tool is easy to use…

This study tests an 8-week online stress management program for health students in Sfax, Tunisia. The program combines cognitive-behavioral therapy and mindfulness meditation through videos, exercises, and motivational messages. Researchers will measure changes in stress, anxiety…

This study tests whether an injection made from human fat cells (Tience®) can safely reduce moderate to severe acne scars. Twenty adults aged 18-40 with scars on their cheeks will receive three treatments on one side of the face over three months. Doctors and participants will tr…

This study explores whether individualized transcranial magnetic stimulation (TMS) can improve symptoms in adults with irritable bowel syndrome (IBS). Participants receive 10 TMS sessions over two weeks, with brain scans and stool tests before and after to understand how the trea…

This study looks at whether playing pickleball for 12 weeks can improve thinking skills like attention and memory, as well as motor skills like balance and strength, in adolescents aged 14-18 with mild intellectual disability. Thirty-two students will either play pickleball three…

This study tests a text-message counseling program designed to help young adults ages 18 to 25 reduce or stop their cannabis use. Participants must use cannabis at least three days a week and live in Tennessee or Colorado. The program uses peer support and counseling delivered vi…

This study looks at whether moderate-to-vigorous aerobic exercise, called Braining, can help people with bipolar depression recover faster and prevent future depressive episodes. Fifty-four participants will be split into three groups: one doing supervised aerobic exercise three …

This study is a health check for students at Constructor University Bremen and employees at HAW-Hamburg. Researchers will use surveys and interviews to measure loneliness, anxiety, stress, and health habits. The goal is to understand what affects wellbeing and find ways to suppor…

This trial tests whether a web-based tool called 'Let's Talk Tech' helps people with mild dementia or mild cognitive impairment and their care partners feel more prepared to make decisions about using technology for home care and safety. Participants use the tool together for up …

This study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…

This study looks at whether giving older adults (ages 60-79) personalized advice and extra support helps them follow brain-healthy habits like a Mediterranean diet, exercise, and staying socially active. Participants have mild memory concerns or are at risk for cognitive decline.…

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …

This study explores whether smartphone sensors can detect early changes in behavior that might signal cognitive decline. About 100 adults aged 65 and older living in assisted living facilities will have an app on their phones that tracks movement, typing patterns, and app usage f…

This early-phase trial is testing whether ketoconazole, a drug normally used for fungal infections, can get into brain tumors (gliomas) in enough amounts to possibly slow their growth. About 80 adults with different grades of glioma will take low doses of the drug before their sc…

This study tests whether adding automatic reminders to echocardiogram (heart ultrasound) reports can increase the number of patients with heart valve disease who see a cardiologist within six months. Researchers will randomly assign 300 patients' reports to receive no prompt, a p…

This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…

This study creates a registry of 240 patients hospitalized with decompensated heart failure with preserved ejection fraction. Researchers will track medical history, body composition, imaging, and blood markers to see how these factors relate to short- and long-term outcomes. The…

This study uses a driving simulator to test whether people with chronic pain can drive safely while taking oral opioids. 450 participants with a valid driver's license will be tested on measures like weaving and reaction time. The goal is to provide better guidance to patients an…

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…

This study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas like CLL and follicular lymphoma. Researchers will ask 250 Korean patients to fill out questionnaires about their well-being and anxiety. The goal is to underst…

This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of disease progression two years after their first treatment. Researchers will combine clinical information with molecular data from 370 patients to build and test this…

This study uses special brain scans (tau PET) to see how anti-amyloid immunotherapy affects tau protein buildup in people with mild Alzheimer's disease. About 135 participants will get two tau PET scans—one before starting treatment and another 12-18 months after finishing it. Th…